Rabbit Recombinant Monoclonal CYP1B1 antibody. C-terminal. Suitable for WB, IHC-P and reacts with Rat, Human samples. Cited in 18 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
Flow Cyt | WB | IHC-P | |
---|---|---|---|
Human | Not recommended | Tested | Tested |
Mouse | Not recommended | Predicted | Predicted |
Rat | Not recommended | Tested | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Human | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/1000 - 1/10000 | Notes - |
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 - 1/500 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:15258110, PubMed:20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:15258110, PubMed:20972997). Exhibits catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2- and 4-hydroxy E1 and E2. Displays a predominant hydroxylase activity toward E2 at the C-4 position (PubMed:11555828, PubMed:12865317). Metabolizes testosterone and progesterone to B or D ring hydroxylated metabolites (PubMed:10426814). May act as a major enzyme for all-trans retinoic acid biosynthesis in extrahepatic tissues. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376, PubMed:15258110). Catalyzes the epoxidation of double bonds of certain PUFA. Converts arachidonic acid toward epoxyeicosatrienoic acid (EpETrE) regioisomers, 8,9-, 11,12-, and 14,15- EpETrE, that function as lipid mediators in the vascular system (PubMed:20972997). Additionally, displays dehydratase activity toward oxygenated eicosanoids hydroperoxyeicosatetraenoates (HpETEs). This activity is independent of cytochrome P450 reductase, NADPH, and O2 (PubMed:21068195). Also involved in the oxidative metabolism of xenobiotics, particularly converting polycyclic aromatic hydrocarbons and heterocyclic aryl amines procarcinogens to DNA-damaging products (PubMed:10426814). Plays an important role in retinal vascular development. Under hyperoxic O2 conditions, promotes retinal angiogenesis and capillary morphogenesis, likely by metabolizing the oxygenated products generated during the oxidative stress. Also, contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression (By similarity).
Cytochrome P450 1B1, CYPIB1, Hydroperoxy icosatetraenoate dehydratase, CYP1B1
Rabbit Recombinant Monoclonal CYP1B1 antibody. C-terminal. Suitable for WB, IHC-P and reacts with Rat, Human samples. Cited in 18 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR14972
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
CYP1B1 also known as cytochrome P450 1B1 is a member of the cytochrome P450 superfamily of enzymes. This monoxygenase enzyme with a molecular mass of approximately 60 kDa plays a role in the metabolism of xenobiotics and endogenous compounds. It is mainly expressed in various tissues including the liver lungs and the artery walls. The enzyme catalyzes the hydroxylation of aromatic hydrocarbons aiding in their detoxification and removal from the body.
CYP1B1 contributes to the metabolism of various drugs and toxins helping to maintain cellular homeostasis. This enzyme also participates in the conversion of steroids and fatty acids impacting hormonal regulation and fatty acid balance. While CYP1B1 does not form a specific complex it functions within the cytochrome P450 enzyme system which collectively metabolizes numerous compounds. This functional integration within a broad enzymatic network highlights its role in chemical transformation processes.
CYP1B1 serves an essential role in the Phase I drug metabolism pathway. This pathway includes the functionalization of xenobiotic substances to prepare them for Phase II reactions. The enzyme is involved in the hydroxylation of substrates which are important steps in both the AhR and chemical carcinogenesis pathways. CYP1B1 interacts with other cytochrome P450 family members such as CYP1A1 which further facilitates the detoxification and clearance of harmful compounds from the body.
CYP1B1 is significantly associated with primary congenital glaucoma and various cancers such as breast cancer. In these conditions altered CYP1B1 activity can lead to atypical metabolism of endogenous hormones contributing to disease progression. CYP1B1's interaction with cyclin D1 is noted in cancer pathogenesis where dysregulation of cell cycle progression occurs. Therefore understanding CYP1B1's expression and function can provide insights into therapeutic strategies targeting these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemical analysis of paraffin-embedded Human renal adenocarcinoma tissue labeling CYP1B1 with ab185954 at 1/500 dilution followed by pre-diluted HRP-conjugated secondary antibody and counter-stained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
Western blot: Anti-CYP1B1 antibody [EPR14972] (ab185954) staining at 1/5000 dilution, shown in black; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab185954 was shown to bind specifically to CYP1B1. A band was observed at 55 kDa in wild-type A549 cell lysates with no signal observed at this size in CYP1B1 knockout cell line Human CYP1B1 knockout A549 cell line ab269476 (knockout cell lysate Human CYP1B1 knockout A549 cell lysate ab269641). To generate this image, wild-type and CYP1B1 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with a high-sensitivity ECL substrate kit and imaged with 8 minutes exposure time. Secondary antibodies used were HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-CYP1B1 antibody [EPR14972] - C-terminal (ab185954) at 1/5000 dilution
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: CYP1B1 knockout A549 cell lysate at 20 µg
Lane 3: HeLa cell lysate at 20 µg
Lane 4: MCF7 cell lysate at 20 µg
Lane 5: SiHa cell lysate at 20 µg
Lane 6: Human Brain cell lysate at 20 µg
Lane 7: Human Kidney cell lysate at 20 µg
Lane 8: Human Liver cell lysate at 20 µg
Lane 9: HepG2 cell lysate at 20 µg
Lane 10: LoVo cell lysate at 20 µg
All lanes: HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 61 kDa
Observed band size: 55 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com